Latest Private Hospitals News

An independent, Rhythm-funded economic model estimates its ColoSTAT blood test could avoid 29,427 public-hospital colonoscopies a year and deliver $72.4 million in net annual hospital savings. The figures strengthen Rhythm’s planned case for Medicare reimbursement, but remain modelled estimates rather than evidence from real-world use.

HealthCo Healthcare and Wellness REIT (ASX: HCW) reported a $49.7 million FY26 statutory loss, suspended distributions and received an unmodified audit opinion that nevertheless highlighted a material uncertainty over its ability to continue as a going concern. The key unresolved issue is the transfer of 10 Healthscope hospitals to alternative operators.

Ramsay Health Care delivered stronger FY26 earnings, a higher fully franked dividend and improved Funding Group leverage as it prepares to separate Ramsay Santé. The proposed demerger remains conditional, but the company has set a clear timetable for the next phase of its portfolio reshaping.

Emyria has reported a sharp increase in FY26 revenue while expanding its psychedelic-assisted therapy network to five operational or announced clinics and 18 beds. Its first Sydney clinic is now fitted out and scheduled to begin treating patients in September, but utilisation and funding remain the next tests.

Ramsay Health Care has finalised its $251 million purchase of National Capital Private Hospital in Canberra, expanding its footprint in key therapeutic areas and expecting earnings accretion within a year.

Integral Diagnostics (ASX: IDX) delivered a robust FY26 with 26% revenue growth to $788.6 million, a 677% surge in profit after tax to $22 million, and a 50% hike in its final dividend to 6 cents per share.

HealthCo Healthcare & Wellness REIT delivered strong FY26 results with 100% rent collection and solid portfolio metrics, while progressing alternative lease arrangements for its Healthscope hospital portfolio.

Vital Healthcare Property Trust (NZX:VHP) delivered a robust FY26, marked by a successful management internalisation, 23.5% AFFO growth, and a stable distribution payout, underpinning its position as a leading healthcare infrastructure owner in Australasia.

Emyria has expanded its Empax clinic network across four states, reporting a 210% revenue increase in FY26 and early clinical success in treatment-resistant depression.

Healius has secured a national pathology services agreement with Ramsay Health Care subsidiaries, consolidating its role across 13 hospitals and stabilising a key revenue stream worth around $45 million annually.

Emyria has trained its first cohort of 31 clinicians in New South Wales, paving the way for its inaugural Sydney Empax clinic at Matilda Nepean, scheduled to open in Q3 2026.

TruScreen has secured clinical validation from the world’s largest cervical screening study in China, setting the stage for rapid market expansion across Asia, Africa, and Europe.